Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.

Abstract

Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral infections are being tested to verify if they might also be effective against SARS-CoV-2, the virus that causes COVID-19. Twenty years ago, the F.D.A. approved Lopinavir/ritonavir (LPV/r) to treat HIV infection. LPV and ritonavir were initially purposed to inhibit 3-chymotrypsin-like protease (3CLpro) of SARS-CoV and MERS-CoV and preliminary promising data on its efficacy for treating people infected with those viruses were available. Therefore, due to the high genetic similarities among those viruses and SARS-CoV-2, early during COVID-19 pandemic LPV/r was also proposed as one emergency treatment. We reviewed data from the literature about LPV/r treatment and SARS-CoV-2 infection, mainly focused on the efficacy and safety of this drugs for COVID-19 treatment. We can conclude that although up to date no clear benefit has been observed with the LPV/r treatment beyond standard care, its efficacy against SARS-COV-2 infection deserves further evaluations, particularly during the very early phase of the disease.

• Authors: Paola Magro, Isabella Zanella, Marta Pescarolo, Francesco Castelli, Eugenia Quiros-Roldan
• Journal: Biomedical journal (Biomed J) Vol. 44 Issue 1 Pg. 43-53 (03 2021) ISSN: 2320-2890 [Electronic] United States
• PMID: 33608241 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Chang Gung University. Published by Elsevier B.V. All rights reserved.

Chemical References

• Drug Combinations
• Lopinavir
• Ritonavir

Topics

• Animals
• Clinical Trials as Topic
• Drug Combinations
• Drug Repositioning
• HIV Infections (drug therapy)
• Humans
• Lopinavir (administration & dosage)
• Ritonavir (administration & dosage)
• SARS-CoV-2
• COVID-19 Drug Treatment